You are here

  • Home
  • Archive
  • Volume 77, Issue 6
  • Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Merrill JT, Shanahan WR, Scheinberg M, et al
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Annals of the Rheumatic Diseases 2018;77:883-889.